NCT01631110View on ClinicalTrials.gov

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Influenza
Interventions
BIOLOGICAL

Inflexal V

Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V

Trial Locations (1)

4123

Covance Clinical Research Unit AG, Allschwil

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT01631110 - Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains | Biotech Hunter | Biotech Hunter